Safety and cardiovascular effects of multiple‐dose administration of aripiprazole and olanzapine in a randomised clinical trial
Human Psychopharmacology: Clinical and Experimental · 2021-01 · 36 (1) · 1-12
DOI: 10.1002/hup.2761 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Human Psychopharmacology: Clinical and Experimental, online erschienen am 29.09.2020. Verfasst von Dora Koller und 11 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology Department, Hospital Universitario de La Princesa, Instituto Teófilo Hernando, School of Medicine, Universidad Autónoma de Madr…. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 70 Literaturangaben. Gefördert von: Consejería de Educación, Juventud y Deporte, Comunidad de Madrid.
Abstract (Originalsprache)
Objective
To assess adverse events (AEs) and safety of aripiprazole (ARI) and olanzapine (OLA) treatment.
Methods
Twenty‐four healthy volunteers receiving five daily oral doses of 10 mg ARI and 5 mg OLA in a crossover clinical trial were genotyped for 46 polymorphisms in 14 genes by qPCR. Drug plasma concentrations were measured by high‐performance liquid chromatography tandem mass spectrometry. Blood pressure (BP) and 12‐lead electrocardiogram were measured in supine position. AEs were also recorded.
Results
ARI decreased diastolic BP on the first day and decreased QTc on the third and fifth day. OLA had a systolic and diastolic BP, heart rate and QTc lowering effect on the first day. Polymorphisms in ADRA2A , COMT , DRD3 and HTR2A genes were significantly associated to these changes. The most frequent adverse drug reactions (ADRs) to ARI were somnolence, headache, insomnia, dizziness, restlessness, palpitations, akathisia and nausea while were somnolence, dizziness, asthenia, constipation, dry mouth, headache and nausea to OLA. Additionally, HTR2A , HTR2C , DRD2 , DRD3 , OPRM1 , UGT1A1 and CYP1A2 polymorphisms had a role in the development of ADRs.
Conclusions
OLA induced more cardiovascular changes; however, more ADRs were registered to ARI. In addition, some polymorphisms may explain the difference in the incidence of these effects among subjects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Pharmacology Department, Hospital Universitario de La Princesa, Instituto Teófilo Hernando, School of Medicine, Universidad Autónoma de Madrid, Instituto de Investigación Sanitaria La Princesa (IP), Madrid, Spa…
- UICEC Hospital Universitario de La Princesa, Platform SCReN (Spanish Clinical Research Network), Instituto de Investigación Sanitaria La Princesa (IP), Madrid, Spain.
- Research Unit, Fundación Burgos por la Investigación de la Salud, Hospital Universitario de Burgos, Burgos, Spain.
ORCID-Profile: Dora Koller, Gina Mejía, Miriam Saiz-Rodríguez, Pablo Zubiaur, Marcos Navares-Gómez, Francisco Abad-Santos
Förderung
- Consejería de Educación, Juventud y Deporte, Comunidad de Madrid
Zitieren
APA
Koller, D., Almenara, S., Mejía, G., Saiz-Rodríguez, M., Zubiaur, P., Román, M., Ochoa, D., Wojnicz, A., Martín, S., Romero-Palacián, D., Navares-Gómez, M., & Abad-Santos, F. (2021). Safety and cardiovascular effects of multiple‐dose administration of aripiprazole and olanzapine in a randomised clinical trial. Human Psychopharmacology: Clinical and Experimental, 36(1), 1-12. https://doi.org/10.1002/hup.2761
Vancouver
Koller D, Almenara S, Mejía G, Saiz-Rodríguez M, Zubiaur P, Román M, et al. Safety and cardiovascular effects of multiple‐dose administration of aripiprazole and olanzapine in a randomised clinical trial. Human Psychopharmacology: Clinical and Experimental. 2021;36(1):1-12. doi:10.1002/hup.2761
BibTeX
@article{Koller2021,
author = {Koller, Dora and Almenara, Susana and Mejía, Gina and Saiz-Rodríguez, Miriam and Zubiaur, Pablo and Román, Manuel and Ochoa, Dolores and Wojnicz, Aneta and Martín, Samuel and Romero-Palacián, Daniel and Navares-Gómez, Marcos and Abad-Santos, Francisco},
title = {Safety and cardiovascular effects of multiple‐dose administration of aripiprazole and olanzapine in a randomised clinical trial},
journal = {Human Psychopharmacology: Clinical and Experimental},
year = {2021},
volume = {36},
number = {1},
pages = {1--12},
doi = {10.1002/hup.2761}
}
EUVIMED